Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma.

ABSTRACT: Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit and depletes peripheral blood eosinophils rapidly. Biomarkers that predict the response to this drug are needed so that microRNAs (miRNAs) can be useful tools. This study was performed with fifteen severe eosinophilic asthmatic patients treated with benralizumab, and serum miRNAs were evaluated before and after treatment by semi-quantitative PCR (qPCR). Patients showed a clinical improvement after benralizumab administration. Additionally, deregulation of miR-1246, miR-5100 and miR-338-3p was observed in severe asthmatic patients after eig

SUBMITTER: Canas JA 

PROVIDER: S-EPMC7912443 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature